Condition: Atypical Hemolytic-Uremic Syndrome · Sponsor: Alexion Pharmaceuticals, Inc.
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Aurora, Colorado, United States | Recruiting |
| Clinical Trial Site | Washington D.C., District of Columbia, United States | Recruiting |
| Clinical Trial Site | Gainesville, Florida, United States | Recruiting |
| Clinical Trial Site | Atlanta, Georgia, United States | Recruiting |
| Clinical Trial Site | Chicago, Illinois, United States | Withdrawn |
| Clinical Trial Site | Boston, Massachusetts, United States | Recruiting |
| Clinical Trial Site | St Louis, Missouri, United States | Recruiting |
| Clinical Trial Site | Winston-Salem, North Carolina, United States | Withdrawn |
| Clinical Trial Site | Columbus, Ohio, United States | Active Not Recruiting |
| Clinical Trial Site 1 | Westmead, New South Wales, Australia | Recruiting |
| Clinical Trial Site 2 | Westmead, New South Wales, Australia | Recruiting |
| Clinical Trial Site | Cairns, Queensland, Australia | Recruiting |
+ 129 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01522183